Jump to content

User:EleanorBrumby/sandbox

From Wikipedia, the free encyclopedia

Professor Alan Boyd[edit]

Professor Alan Keith Boyd BSc (Hons) MB ChB FRSB FFLM FRCP FFPM FMedSci (born 16 November 1954) is the Past-President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians[1], CEO and founder of Boyd Consultants Ltd[2] and a Pharmaceutical Physician. Professor Boyd has made leading contributions to developing medicines in industry, facilitated numerous drug development programmes with academics, and driven the recognition for the new specialty of Pharmaceutical Medicine.

His industry work developed multiple products that are now approved medicines for a wide range of indications. He is globally recognised as a pioneer in gene-based therapies[3], having led the development of the first gene therapy to be submitted for regulatory approval and being involved in nine of the ATMPs that are now approved medicines. As a Fellow of the Faculty of Pharmaceutical Medicine he played a key role in establishing a postgraduate speciality programme which has supported GMC accreditation of 400 post-graduate trainees receiving a CCT in the specialty.

Early life and education[edit]

Alan attended Blackpool Collegiate Grammar School (1966 - 1973) and went on to the University of Birmingham from the years 1974 - 1980 in which he became a graduate in Biochemistry and Medicine.

Qualifications[edit]

BSc (Hons) Medical Biochemical Studies, University of Birmingham 1977  
MB ChB University of Birmingham 1980
DPM Diploma in Pharmaceutical Medicine, Royal Colleges of Physicians 1987
MFPM Founder Member of Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians 1989  
FFPM Elected Fellow of Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians 1996
FRSB Elected Fellow of the Royal Society of Biology, UK 2013
FRCP Elected Fellow of the Royal College of Physicians, London 2018
FFLM Elected Honorary Fellow of the Faculty of Forensic and Legal Medicine, Royal Colleges of Physicians[4] 2019

Pharmaceutical Industry Career[edit]

Professor Boyd began his pharmaceutical industry career in 1984 where he worked for Glaxo Group Research Limited (1984 - 1986) as a clinical pharmacologist, focusing on the earlier stages of drug development. From 1988 he led ICI Pharma's cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada. In 1995 Alan became the Global Head of Medical Research for Zeneca Pharmaceuticals and was responsible for the global medical development of all their products.

After four years as Global Head of Medical Research at Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company. In particular, he led the development of their gene therapy based medicines portfolio.

Ark Therapeutics grew into an established healthcare company with five products in the company’s portfolio, the lead product being Cerepro®, for Malignant Glioma. Alan led the development of these gene-based therapies and it is of note that Cerepro® was the first gene therapy to be submitted to the European Medicines Agency for approval as a prescription medicine.[5] Although it did not subsequently receive regulatory approval, the Marketing Authorisation Application filing of Cerepro® and its review by the EMA[6][7][8], paved the way for the other cell and gene-based therapies that followed it and helped set the future standards as required by the various Regulatory Agencies worldwide.

In April 2005, he left to set up Boyd Consultants, the focus of which is to aid and support early-stage life-science based companies and academic groups develop their research ideas into potential medicines. His clients now include many companies in Europe, North America and Japan who are devoted to the development of medical drug products, devices and in vitro devices.

A graduate in Biochemistry and Medicine from the University of Birmingham, UK, Professor Boyd is also a Fellow and Past-President of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He was previously Chair of the Specialist Advisory Committee in Pharmaceutical Medicine at The Royal College of Physicians, United Kingdom.

In November 2009 he was appointed an Honorary Professor at the College of Medical and Dental Sciences at the University of Birmingham Medical School, in recognition of his expertise in medicines development.

Non-Executive Director appointments[edit]

Company Board member title Duration
Genable Technologies Ltd Non-Executive Director September 2005 - March 2016
Celentyx Ltd Non-Executive Director November 2005 - Date (present)[9]
Laurantis Pharma Ltd Non-Executive Director May 2008 - October 2014
Bioscience Ventures Ltd Non-Executive Director November 2010 - June 2016[10]
Alta Bioscience Ltd Non-Executive Director November 2010 - June 2016[11]
Linear Diagnostics Ltd Non-Executive Director October 2013 - September 2017[12]
Clinigen Group Ltd Non-Executive Director November 2018 - Date (present)[13]
Transine Therapeutics Ltd Non-Executive Director December 2019 - Date (present)[14]
Stablepharma Ltd Advisory Board Member August 2021 - Date (present)[15]
Taysha Gene Therapies, Inc Advisory Board Member February 2021 - Date (present)[16]

Personal Life[edit]

Association Memberships[edit]

Fellowships and Awards[edit]

Publications[edit]

Further reading[edit]

Professor Alan Boyd was quoted in an article titled 'Gene genius' in Raconteur's 'Future of Healthcare' report published in The Times (27/07/22)[34]. The article discussed the recent developments of gene therapies and cutting edge medicines.


References[edit]

  1. ^ Strange, Will (2019-11-30). "Reflections from our past presidents". FPM. Retrieved 2022-08-09.
  2. ^ "Professor Alan Boyd". Boyds. Retrieved 2022-08-09.
  3. ^ "Professor Alan Boyd | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 2022-08-09.
  4. ^ "Honorary Fellows". FFLM. Retrieved 2022-08-03.
  5. ^ European Medicines Agency (19/07/2007). "Cerepro: Withdrawal of the marketing authorisation application". {{cite web}}: Check date values in: |date= (help)
  6. ^ European Medicines Agency (26/04/2007). "WITHDRAWAL ASSESSMENT REPORT FOR CEREPRO" (PDF). {{cite web}}: Check date values in: |date= (help)
  7. ^ Mitchell, Peter (2010-03-01). "Ark's gene therapy stumbles at the finish line". Nature Biotechnology. 28 (3): 183–184. doi:10.1038/nbt0310-183. ISSN 1546-1696.
  8. ^ "Ark drops Cerepro appeal and lifts for sale sign". Evaluate.com. 2010-03-09. Retrieved 2022-08-09.
  9. ^ "Celentyx Ltd | Our Team". Celentyx Ltd | Immunology CRO. Retrieved 2022-08-09.
  10. ^ "BIOSCIENCE VENTURES LIMITED people - Find and update company information - GOV.UK". find-and-update.company-information.service.gov.uk. Retrieved 2022-08-09.
  11. ^ "ALTA BIOSCIENCE LIMITED people - Find and update company information - GOV.UK". find-and-update.company-information.service.gov.uk. Retrieved 2022-08-09.
  12. ^ "LINEAR DIAGNOSTICS LIMITED people - Find and update company information - GOV.UK". find-and-update.company-information.service.gov.uk. Retrieved 2022-08-09.
  13. ^ Clingen Group Ltd (10/11/2018). "Board appointment". Clinigengroup. {{cite web}}: Check date values in: |date= (help)
  14. ^ "Our Board - Transine Therapeutics". transinetx.com. Retrieved 2022-08-09.
  15. ^ "Prof. Alan Boyd". Stablepharma. Retrieved 2022-10-12.
  16. ^ "Alan Boyd, B.Sc., M.B., Ch.B., FRSB, FFLM, FRCP, FFPM | Taysha GTx". 2021-01-29. Retrieved 2022-10-12.
  17. ^ "Professor Alan Boyd elected President of FPM". European Pharmaceutical Review. Retrieved 2022-08-03.
  18. ^ "Bionow Award Winners!". Perfectus Biomed. 2016-11-28. Retrieved 2022-08-03.
  19. ^ [email protected] (2018-09-11). "Boyds presented with Queen's Award for Enterprise". Boyds. Retrieved 2022-08-03.{{cite web}}: CS1 maint: numeric names: authors list (link)
  20. ^ "Honorary Fellows". FFLM. Retrieved 2022-08-03.
  21. ^ sccci. "Previous Awards". South Cheshire Chamber of Commerce & Industry. Retrieved 2022-08-03.
  22. ^ "The Dudley Buxton Prize | The Royal College of Anaesthetists". rcoa.ac.uk. Retrieved 2022-08-03.
  23. ^ Strange, Will (2021-05-12). "Professor Alan Boyd awarded the Fellowship of the Academy of Medical Sciences". FPM. Retrieved 2022-08-03.
  24. ^ "Cheshire Life Magazine". www.cheshirelifemagazine.co.uk. Retrieved 2022-08-03.
  25. ^ Meredith, Joe (2022-07-06). "Professor Alan Boyd is awarded President's Medal". FPM. Retrieved 2022-08-03.
  26. ^ "Professor Alan Boyd awarded FPM President's Medal". Boyds. 2022-07-07. Retrieved 2022-08-03.
  27. ^ Boorjian, Stephen A.; Alemozaffar, Mehrdad; Konety, Badrinath R.; Shore, Neal D.; Gomella, Leonard G.; Kamat, Ashish M.; Bivalacqua, Trinity J.; Montgomery, Jeffrey S.; Lerner, Seth P.; Busby, Joseph E.; Poch, Michael (2021-01). "Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial". The Lancet. Oncology. 22 (1): 107–117. doi:10.1016/S1470-2045(20)30540-4. ISSN 1474-5488. PMC 7988888. PMID 33253641. {{cite journal}}: Check date values in: |date= (help)
  28. ^ Boyd, Alan (2021-10). "Commentary on "Regulatory Science and Innovation Programme for Europe (ReScIPE): A proposed model"". British Journal of Clinical Pharmacology. 87 (10): 3647–3648. doi:10.1111/bcp.14813. ISSN 1365-2125. PMID 33742699. {{cite journal}}: Check date values in: |date= (help)
  29. ^ Stonier, Peter D.; Silva, Honorio; Boyd, Alan; Criscuolo, Domenico; Gabbay, Felicity J.; Imamura, Kyoko; Kesselring, Gustavo; Kerpel-Fronius, Sandor; Klech, Heinrich; Klingmann, Ingrid (2020). "Evolution of the Development of Core Competencies in Pharmaceutical Medicine and Their Potential Use in Education and Training". Frontiers in Pharmacology. 11. doi:10.3389/fphar.2020.00282/full. ISSN 1663-9812.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  30. ^ Morris, Thomas; Brostoff, Joshua M.; Stonier, Peter David; Boyd, Alan (2020). "Evolution of Ethical Principles in the Practice of Pharmaceutical Medicine From a UK Perspective". Frontiers in Pharmacology. 10. doi:10.3389/fphar.2019.01525/full. ISSN 1663-9812.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  31. ^ Boyd, Alan; Cottam, Ben; Obiora, Konrad; Stonier, Peter (2017). "The Faculty of Pharmaceutical Medicine – Foundation, function and future". Journal of Medicines Development Sciences. 3 (1): 193.
  32. ^ Shore, Neal D.; Boorjian, Stephen A.; Canter, Daniel J.; Ogan, Kenneth; Karsh, Lawrence I.; Downs, Tracy M.; Gomella, Leonard G.; Kamat, Ashish M.; Lotan, Yair; Svatek, Robert S.; Bivalacqua, Trinity J. (2017-10-20). "Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 35 (30): 3410–3416. doi:10.1200/JCO.2017.72.3064. ISSN 1527-7755. PMC 5648171. PMID 28834453.
  33. ^ Webster, Scott P.; McBride, Andrew; Binnie, Margaret; Sooy, Karen; Seckl, Jonathan R.; Andrew, Ruth; Pallin, T. David; Hunt, Hazel J.; Perrior, Trevor R.; Ruffles, Vincent S.; Ketelbey, J. William (2017-03). "Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™)". British Journal of Pharmacology. 174 (5): 396–408. doi:10.1111/bph.13699. ISSN 1476-5381. PMC 5301048. PMID 28012176. {{cite journal}}: Check date values in: |date= (help)
  34. ^ 0. "Future of Healthcare 2022". Raconteur. Retrieved 2022-08-09. {{cite web}}: |last= has numeric name (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:EleanorBrumby/sandbox&oldid=1189872174"